All lobbying filings

ROBERTI GLOBAL (FKA ROBERTI WHITE, LLC)

ROBERTI GLOBAL (FKA ROBERTI WHITE, LLC) filed a Q2 report for AMERICAN PHARMACIES, INC. on July 16, 2026, reporting $60,000 in lobbying income.

Lobbying for AMERICAN PHARMACIES, INC. · Independent pharmacy services group

All filings by ROBERTI GLOBAL (FKA ROBERTI WHITE, LLC) · Everything AMERICAN PHARMACIES, INC. has reported

Filing · LD-2 quarterly report Q2 report

Reporting period

2nd Quarter 2026

Apr 1 - June 30 · Posted Jul 16, 2026

Income

$60,000

What the client paid this registrant for the period.

Client based in

Texas

Official filing document

Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 3

Pharmacy

Issues related to independent pharmacy, pharmacy benefit manager practices, prescription drug access and affordability, pharmacy networks, reimbursement, contract terms, patient steering, spread pricing, direct and indirect remuneration fees, rebate and fee transparency, audit rights, claims data transparency, vertical integration, affiliated pharmacy arrangements, mail-order and specialty pharmacy practices, any-willing-pharmacy protections, network adequacy, pharmacy access standards, and policies affecting family-owned and community pharmacies in the commercial market.

Medicare/Medicaid

Issues related to independent pharmacy in Medicare, Medicaid, and other federal health programs, including Medicare Part D pharmacy access and reimbursement, Medicaid managed care pharmacy reimbursement, PBM spread pricing, direct and indirect remuneration fees, rebate and fee pass-through, pharmacy network adequacy, preferred pharmacy networks, patient steering, mail-order and specialty pharmacy practices, vertical integration, affiliated pharmacy arrangements, essential retail pharmacy access, any-willing-pharmacy protections, long-term care pharmacy access, pharmacist-provided services, Medicare drug pricing implementation, and policies affecting beneficiary access to community pharmacies.

Defense

Issues related to the TRICARE pharmacy program; NDAA reauthorization.

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.